Cargando…
Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
PURPOSE: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811795/ https://www.ncbi.nlm.nih.gov/pubmed/31687050 http://dx.doi.org/10.1155/2019/9529053 |
_version_ | 1783462538973806592 |
---|---|
author | Tymińska, Agata Kapłon-Cieślicka, Agnieszka Ozierański, Krzysztof Budnik, Monika Wancerz, Anna Sypień, Piotr Peller, Michał Balsam, Paweł Opolski, Grzegorz Filipiak, Krzysztof J. |
author_facet | Tymińska, Agata Kapłon-Cieślicka, Agnieszka Ozierański, Krzysztof Budnik, Monika Wancerz, Anna Sypień, Piotr Peller, Michał Balsam, Paweł Opolski, Grzegorz Filipiak, Krzysztof J. |
author_sort | Tymińska, Agata |
collection | PubMed |
description | PURPOSE: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). METHODS: A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017. Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up). The primary endpoint was HF onset at one-year follow-up. Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year. RESULTS: Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and p < 0.001 and 31.4 ng/mL and p = 0.001, respectively). Patients who reached the primary endpoint (50 patients (48%)) had significantly higher baseline concentrations of both biomarkers and a higher Gal-3 level at one year compared to patients who did not. Both Gal-3 and sST2 were predictors of the primary endpoint in univariate logistic regression analysis, but only Gal-3 remained significant in multivariate analysis. There was no clear association between both biomarkers and echocardiographic parameters. CONCLUSIONS: Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI. However, only Gal-3 was the independent predictor of HF development at one-year observation. This trial is registered with NCT03735719. |
format | Online Article Text |
id | pubmed-6811795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-68117952019-11-04 Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction Tymińska, Agata Kapłon-Cieślicka, Agnieszka Ozierański, Krzysztof Budnik, Monika Wancerz, Anna Sypień, Piotr Peller, Michał Balsam, Paweł Opolski, Grzegorz Filipiak, Krzysztof J. Dis Markers Research Article PURPOSE: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). METHODS: A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017. Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up). The primary endpoint was HF onset at one-year follow-up. Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year. RESULTS: Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and p < 0.001 and 31.4 ng/mL and p = 0.001, respectively). Patients who reached the primary endpoint (50 patients (48%)) had significantly higher baseline concentrations of both biomarkers and a higher Gal-3 level at one year compared to patients who did not. Both Gal-3 and sST2 were predictors of the primary endpoint in univariate logistic regression analysis, but only Gal-3 remained significant in multivariate analysis. There was no clear association between both biomarkers and echocardiographic parameters. CONCLUSIONS: Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI. However, only Gal-3 was the independent predictor of HF development at one-year observation. This trial is registered with NCT03735719. Hindawi 2019-10-10 /pmc/articles/PMC6811795/ /pubmed/31687050 http://dx.doi.org/10.1155/2019/9529053 Text en Copyright © 2019 Agata Tymińska et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tymińska, Agata Kapłon-Cieślicka, Agnieszka Ozierański, Krzysztof Budnik, Monika Wancerz, Anna Sypień, Piotr Peller, Michał Balsam, Paweł Opolski, Grzegorz Filipiak, Krzysztof J. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction |
title | Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction |
title_full | Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction |
title_fullStr | Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction |
title_full_unstemmed | Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction |
title_short | Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction |
title_sort | association of galectin-3 and soluble st2, and their changes, with echocardiographic parameters and development of heart failure after st-segment elevation myocardial infarction |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811795/ https://www.ncbi.nlm.nih.gov/pubmed/31687050 http://dx.doi.org/10.1155/2019/9529053 |
work_keys_str_mv | AT tyminskaagata associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT kapłoncieslickaagnieszka associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT ozieranskikrzysztof associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT budnikmonika associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT wancerzanna associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT sypienpiotr associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT pellermichał associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT balsampaweł associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT opolskigrzegorz associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction AT filipiakkrzysztofj associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction |